BlackRock’s Inhibrx INBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$78.3M Buy
825,972
+27,074
+3% +$2.71M ﹤0.01% 2368
2026
Q1
$53.7M Buy
798,898
+21,515
+3% +$1.6M ﹤0.01% 2457
2025
Q4
$61.4M Buy
777,383
+92,637
+14% +$6.31M ﹤0.01% 2390
2025
Q3
$23.1M Sell
684,746
-43,998
-6% -$1.08M ﹤0.01% 3010
2025
Q2
$10.4M Sell
728,744
-103,988
-12% -$1.34M ﹤0.01% 3396
2025
Q1
$11.6M Buy
832,732
+925
+0.1% +$12.6K ﹤0.01% 3239
2024
Q4
$12.8M Buy
831,807
+114,654
+16% +$1.75M ﹤0.01% 3293
2024
Q3
$11.2M Buy
717,153
+34,078
+5% +$479K ﹤0.01% 3338
2024
Q2
$9.68M Buy
+683,075
New +$10.7M ﹤0.01% 3403

Other funds holding INBX

BlackRock's INBX Position: Q2 2026 in Review

BlackRock increased its Inhibrx (INBX) stake by 3.4% in Q2 2026, buying an estimated $2.71M and bringing the position to 825,972 shares worth $78.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2368.

BlackRock first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • BlackRock held 825,972 shares of Inhibrx worth $78.3M as of Q2 2026.
  • BlackRock bought 27,074 Inhibrx shares in Q2 2026, an estimated $2.71M.
  • Inhibrx made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2368 holding.
  • BlackRock first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.